OrthoPure XT Multiligament PMCF Study

  • Research type

    Research Study

  • Full title

    POST MARKET CLINICAL FOLLOW-UP OF ORTHOPURE XT FOR THE TREATMENT OF MULTILIGAMENT INJURED KNEES: A CASE SERIES

  • IRAS ID

    314147

  • Contact name

    Ian Dos Remedios

  • Contact email

    Ian.dosremedios@uhnm.nhs.uk

  • Sponsor organisation

    TRX Orthopaedics Ltd

  • Clinicaltrials.gov Identifier

    NCT05655156

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    The OrthoPure XT device is a xenograft tissue scaffold that is intended to be used to treat patients that are suffering with knee ligament injuries to restore their knee function and stability. Knee ligaments are short bands of though, flexible tissue that hold the knee together. Xenograft is tissue or organ made from one species and transplanted into another. The OrthoPure XT device xenograft is made from porcine. The device is approved for use in the EU and UK for ligament reconstruction.
    This study is looking to identify any residual risks during multi-ligament knee reconstruction and to continue evaluation of the device safety and performance so no new risk arise during multi-ligament knee reconstruction.
    For patients that choose to participate in the study, data will be collected on the device and their knee function from before the knee surgery and up to 2 years after the surgery. Subjects will attend a pre-operative visit before the surgery, intra-operative visit (same day as device implant), and follow-up visits at 1 month, 3 months, 6 months, 1 year and 2 years after the surgery.

  • REC name

    South East Scotland REC 02

  • REC reference

    23/SS/0056

  • Date of REC Opinion

    19 Jun 2023

  • REC opinion

    Further Information Favourable Opinion